Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211159
Status:
COMPLETED
Last Update Posted:
2017-07-31
First Post:
2005-09-13
Brief Title:
OmegAD Omega-3 and Alzheimers Disease
Sponsor:
Karolinska University Hospital
Organization:
Karolinska University Hospital
Study Overview
Official Title:
Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimers Disease OmegAD a Randomized Double-blind Trial
Status:
COMPLETED
Status Verified Date:
2005-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Memory loss and difficulties with thinking associated with Alzheimers disease AD may be due to a deficiency in the brain of a fatty acid named DHA The aim of this trial is to see if dietary supplementation with a preparation rich in DHA will halt cognitive impairment in AD patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None